Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA Extends Enhanced Drug Distribution Security Requirements Deadline

The agency has announced a one-year delay in the DSCSA requirements for system-wide electronic interoperable systems to be put in place and how to request a waiver, exception, or exemption.

Fda Building

In a recently released FDA final guidance, entitled “Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act—Compliance Policies,” the FDA announced a one-year delay on the deadline for manufacturers and their trading partners to comply with the Drug Supply Chain Security Act’s final enhanced drug distribution security requirements, as described in the same document. Previously, the deadline was November 27 of this year.

The delay specifically addresses the requirements for system-wide electronic interoperable systems to be put in place to track products throughout the supply chain. It also applies to the processing of saleable returns. The same FDA guidance describes the compliance policies the FDA will employ regarding the enforcement of requirements for interoperable, electronic, package-level product tracing and provides information to help supply chain partners in their efforts to comply with the requirements for tracing at the package level.

The FDA also recently issued a guidance called “Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act,” which describes the process a trading partner or other stakeholder should use to request a waiver, exception, or exemption from the requirements of the Federal Food, Drug, and Cosmetic Act, as well as the factors the FDA will consider when it evaluates one of these requests from an authorized trading partner or other stakeholder. Additionally, this guidance describes the process the FDA intends to follow once every two years to review and make determinations on renewing a previously approved waiver, exception, or exemption, where applicable.

Requests for waivers, exceptions, and exemptions should be submitted through the FDA’s CDER NextGen Portal page.    

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging